138 related articles for article (PubMed ID: 20979036)
21. Distribution of alpha-galactosidase A in normal human kidney and renal accumulation and distribution of recombinant alpha-galactosidase A in Fabry mice.
Christensen EI; Zhou Q; Sørensen SS; Rasmussen AK; Jacobsen C; Feldt-Rasmussen U; Nielsen R
J Am Soc Nephrol; 2007 Mar; 18(3):698-706. PubMed ID: 17287429
[TBL] [Abstract][Full Text] [Related]
22. [Heterozygous Fabry's disease. Case report with electron microscopic studies].
Luderschmidt C; Wolff HH
Hautarzt; 1980 Jul; 31(7):372-5. PubMed ID: 6249775
[TBL] [Abstract][Full Text] [Related]
23. [Neuropathic pain in a young female patient with Fabry's disease: a new mutation of the alpha-galactosidase A gene].
Politei JM; Pagano MA; Dubrovsky A; Pereira F; Matte U; Burin M; Giugliani R
Rev Neurol; 2005 Oct 16-31; 41(8):506-7. PubMed ID: 16224739
[No Abstract] [Full Text] [Related]
24. Renal involvement in Fabry's disease.
Okuda S
Intern Med; 2000 Aug; 39(8):601-2. PubMed ID: 10939529
[No Abstract] [Full Text] [Related]
25. [Current management of Fabry disease].
Cochat P; Liutkus A; Dubourg L; Levade T
Nephrol Ther; 2006 Jan; 2 Suppl 2():S167-71. PubMed ID: 17373218
[TBL] [Abstract][Full Text] [Related]
26. Fabry's disease with partially deficient hydrolysis of ceramide trihexoside.
Kobayashi T; Kira J; Shinnoh N; Goto I; Kuroiwa Y
J Neurol Sci; 1985 Feb; 67(2):179-85. PubMed ID: 2984338
[TBL] [Abstract][Full Text] [Related]
27. Subclinical Fabry's disease occurring in the context of IgA nephropathy.
Kawamura O; Sakuraba H; Itoh K; Suzuki Y; Doi M; Kuwabara H; Oshima S; Abe S; Warabi H; Yoshizawa N
Clin Nephrol; 1997 Feb; 47(2):71-5. PubMed ID: 9049452
[TBL] [Abstract][Full Text] [Related]
28. Neurophysiological, behavioral and morphological abnormalities in the Fabry knockout mice.
Rodrigues LG; Ferraz MJ; Rodrigues D; Pais-Vieira M; Lima D; Brady RO; Sousa MM; Sá-Miranda MC
Neurobiol Dis; 2009 Jan; 33(1):48-56. PubMed ID: 18848893
[TBL] [Abstract][Full Text] [Related]
29. An atypical variant of Fabry's disease in men with left ventricular hypertrophy.
Nakao S; Takenaka T; Maeda M; Kodama C; Tanaka A; Tahara M; Yoshida A; Kuriyama M; Hayashibe H; Sakuraba H
N Engl J Med; 1995 Aug; 333(5):288-93. PubMed ID: 7596372
[TBL] [Abstract][Full Text] [Related]
30. [Visceral manifestations of glycosphingolipidosis (Fabry's disease)].
Zaĭrat'iants OV; Bruk EI; Berestova AV; Mendel'son MM
Arkh Patol; 1987; 49(6):58-63. PubMed ID: 3117021
[TBL] [Abstract][Full Text] [Related]
31. Dysregulated autophagy contributes to podocyte damage in Fabry's disease.
Liebau MC; Braun F; Höpker K; Weitbrecht C; Bartels V; Müller RU; Brodesser S; Saleem MA; Benzing T; Schermer B; Cybulla M; Kurschat CE
PLoS One; 2013; 8(5):e63506. PubMed ID: 23691056
[TBL] [Abstract][Full Text] [Related]
32. Update on Fabry disease: kidney involvement, renal progression and enzyme replacement therapy.
Breunig F; Wanner C
J Nephrol; 2008; 21(1):32-7. PubMed ID: 18264934
[TBL] [Abstract][Full Text] [Related]
33. Fabry disease cardiomyopathy: from genes to clinical manifestations.
Kertész AB; Édes I
Curr Pharm Biotechnol; 2012 Oct; 13(13):2477-84. PubMed ID: 22280422
[TBL] [Abstract][Full Text] [Related]
34. Fabry disease: treatment and diagnosis.
Rozenfeld PA
IUBMB Life; 2009 Nov; 61(11):1043-50. PubMed ID: 19859978
[TBL] [Abstract][Full Text] [Related]
35. Cytoplasmic inclusions of Fabry's disease. Ultrastructural demonstration of their presence in urine sediment.
Tubbs RR; Gephardt GN; McMahon JT; Hall PM; Gifford RW
Arch Pathol Lab Med; 1981 Jul; 105(7):361-2. PubMed ID: 6264885
[TBL] [Abstract][Full Text] [Related]
36. Impact of enzyme replacement therapy on cardiac morphology and function and late enhancement in Fabry's cardiomyopathy.
Lui CY; Ju H
Am J Cardiol; 2006 Dec; 98(11):1557-8. PubMed ID: 17126672
[No Abstract] [Full Text] [Related]
37. In vitro study of encapsulation therapy for Fabry disease using genetically engineered CHO cell line.
Naganawa Y; Ohsugi K; Kase R; Date I; Sakuraba H; Sakuragawa N
Cell Transplant; 2002; 11(4):325-9. PubMed ID: 12162373
[TBL] [Abstract][Full Text] [Related]
38. [Fabry's disease and hypoparathyroidism].
Misery L; Gregoire M; Prieur F; Froissart R; Guffon N; Maitre S; Fond L; Denis L; Perrot JL; Cambazard F
Ann Med Interne (Paris); 2002 Jun; 153(4):283-5. PubMed ID: 12218896
[TBL] [Abstract][Full Text] [Related]
39. Fabry's disease: long-term study of a family.
Arias Martínez N; Barbado Hernández FJ; García Consuegra J; López Rodríguez M; Gil Guerrero L; Gómez-Cerezo J; Casal Esteban V; Vázquez Rodríguez JJ
Eur J Intern Med; 2004 Jul; 15(4):210-215. PubMed ID: 15288673
[TBL] [Abstract][Full Text] [Related]
40. Fabry disease with special reference to neurological manifestations.
Banerjee TK
Eur Rev Med Pharmacol Sci; 2004; 8(6):275-81. PubMed ID: 15745387
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
